Status:
UNKNOWN
Viscoelasticity Imaging to Assess Liver Cancer
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsors:
Siemens Corporation, Corporate Technology
Fonds de la Recherche en Santé du Québec
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Ultrasound (US) used for hepatocellular carcinoma (HCC) surveillance suffers from low sensitivity (60-78%) due to fatty liver, obesity, and diffusely nodular appearance in cirrhosis. Once a suspicious...
Detailed Description
RESEARCH QUESTION AND BACKGROUND: Primary liver cancer or hepatocellular carcinoma (HCC) is the fifth most common cancer in men and the seventh in women and is the second cause of cancer mortality wor...
Eligibility Criteria
Inclusion
- Are at least 18 years old at screening;
- Able to comprehend and willingness to provide voluntary consent;
- Are able to have a MRI;
- Understand French or English;
- Patients enrolled in a monitoring program or referred for the characterization of a focal liver lesion;
- Focal liver lesion is visible during ultrasound screening in B-mode.
Exclusion
- Are pregnant or trying to become pregnant;
- Have a weight or girth preventing from entering the MR magnet bore;
- Are unable to understand or unwilling to provide written informed consent for this study;
- Have a contraindication to MRI (pacemaker, insurmountable claustrophobia);
- Have chronic kidney disease preventing the injection of gadolinium-based contrast agent.
Key Trial Info
Start Date :
October 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 22 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04409340
Start Date
October 5 2020
End Date
December 22 2023
Last Update
October 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 0A9